Buscar en
Farmacia Hospitalaria (English Edition)
Toda la web
Inicio Farmacia Hospitalaria (English Edition) Assessing lenalidomide for treating multiple myeloma, myelofibrosis and myelodys...
Journal Information
Vol. 34. Issue 5.
Pages 218-223 (January 2010)
Download PDF
More article options
Vol. 34. Issue 5.
Pages 218-223 (January 2010)
Original Article
Full text access
Assessing lenalidomide for treating multiple myeloma, myelofibrosis and myelodysplastic syndrome
Evaluación de lenalidomida en el tratamiento del mieloma múltiple, la mielofibrosis y el síndrome mielodisplásico
C. Hernández Pratsa,
Corresponding author

Corresponding author.
, F. Romero Iborraa, E. Arroyo Domingoa, I. Castillo Valerob, M. Real Paniselloa, M.I. Sánchez Casadoa
a Servicio de Farmacia, Hospital General de Elda, Alicante, Spain
b Servicio de Hematología, Hospital General de Elda, Alicante, Spain
Article information
Download PDF

Lenalidomide (LDM) is an immunomodulatory and anti-angiogenic drug which has been shown to be effective in several haematological disorders (multiple myeloma [MM], myeloid metaplasia with myelofibrosis [MF] and myelodysplastic syndrome [MDS]). The objective of this study is to evaluate the effectiveness and tolerability of LDM in our patients.


Retrospective observational study which included patients at our hospital who were monitored by the haematology unit, diagnosed with MM, MF and MDS and candidates for LDM treatment. Treatment effectiveness was assessed after approximately 4 cycles of treatment.


Between February 2007 and March 2008, 16 patients were listed as candidates for receiving treatment with LDM (50% female/50% male, with a mean age of 69.6 years); of these candidates, 3 never initiated treatment. Five of the six patients with MM treated at our hospital obtained some sort of response (83.3%). Of the 4 patients with MF, 2 (66.6%) experienced some sort of response to treatment. Of the 6 patients diagnosed with MDS, treatment was initiated in 3, and it had to be suspended in 2 cases due to different reasons. Treatment only had to be suspended in two of the 13 patients who began it (15.4%) due to adverse effects (AE).


LDM is well-tolerated and produces sustained clinical benefits, especially in MM and MF. More studies are needed for in-depth examination of treatment duration, new indications and the use of treatments combined with other drugs.

Myelodysplastic syndrome
Multiple myeloma

La lenalidomida (LDM) es un agente inmunomodulador y antiangiogénico que ha demostrado su eficacia en varios trastornos hematológicos (mieloma múltiple [MM], metaplasma mieloide con mielofibrosis [MF] y síndrome mielodisplásico [SMD]). El objetivo de este estudio fue evaluar la efectividad y la tolerabilidad de la LDM en nuestros pacientes.


Estudio retrospectivo observacional que incluyó a los pacientes de nuestro hospital en seguimiento por la consulta de Hematología que fueron diagnosticados de MM, MF y SMD, y que eran candidatos a recibir tratamiento con LDM. La evaluación de la eficacia se realizó transcurridos aproximadamente 4 ciclos desde el inicio del tratamiento.


Desde febrero de 2007 hasta marzo de 2008 fueron 16 los pacientes candidatos a recibir tratamiento con LDM (50% mujeres, 50% varones, con una edad media de 69,6 años), aunque 3 de ellos no llegaron a iniciarlo. De los 6 pacientes con MM tratados en nuestro hospital, 5 de ellos obtuvieron algún tipo de respuesta (83,3%). De los 4 pacientes con MF, 2 (66,6%) experimentaron algún tipo de respuesta al tratamiento. De los 6 pacientes diagnosticados de SMD, únicamente se inició el tratamiento en 3, y en 2 de ellos se tuvo que suspender por distintas causas. Destacamos que únicamente hubo que suspender el tratamiento en dos de los 13 pacientes que lo iniciaron (15,4%) por los efectos adversos.


La LDM consigue, con buena tolerancia, beneficio clínico mantenido sobre todo en el MM y la MF. Son necesarios más estudios que profundicen en la duración del tratamiento, en nuevas indicaciones y en el uso de tratamientos combinados con otros agentes.

Palabras clave:
Síndrome mielodisplásico
Mieloma múltiple
Full text is only aviable in PDF
J.B. Aragon-Ching, L. Haiquing, E.R. Gardner, W.D. Figg.
Thalidomide analogues as anticancer drugs.
Recent Patents Drug Discov, 2 (2007), pp. 167-2766
J. San Miguel, J.L. Harousseau, D. Joshua, K.C. Anderson.
Individualizing treatment of patients with myeloma in the era of novel agents.
J Clin Oncol, 26 (2008), pp. 2761-2766
A. Palumbo, M. Dimopoulos, J. San Miguel, J.L. Harousseau, M. Attal, M. Hussein, et al.
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Blood Rev, 23 (2009), pp. 87-93
S. Singhal, J. Mehta.
Multiple myeloma.
Clin J Am Soc Nephrol, 1 (2006), pp. 1322-1330
R. Govindarajan, S. Jagannath, J.T. Flick, D.H. Vesole, J. Sawyer, B. Barlogie, et al.
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.
Br J Haematol, 95 (1996), pp. 349-353
B. Barlogie, L. Smith, R. Alexanian.
Effective treatment of advanced multiple myeloma refractory to alkylating agents.
N Engl J Med, 310 (1984), pp. 1353-1356
M. Dimopoulos, D. Weber, C. Chen.
Evaluating oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma.
Haematologica, 90 (2005), pp. 160
M. Lacy, M. Gertz, A. Dispenxieri.
Lenalidomide plus dexamethasone in newly diagnosed myeloma: response to therapy, time to progression, and survival (abstract).
Blood, 108 (2006), pp. 239a
A. Tefferi.
Myelofibrosis with myeloid metaplasia.
N Engl J Med, 342 (2000), pp. 1255-1265
C.S. Chim, Y.L. Kwong, A.K. Lie, S.K. Ma, C.C. Chan, L.G. Wong, et al.
Long-term outcome of 231 patients with essential thrombocythemia: Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
Arch Intern Med, 165 (2005), pp. 2651-2658
M. Marchetti, G. Barosi, F. Balestri, G. Viarengo, S. Gentili, S. Barulli, et al.
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial.
J Clin Oncol, 22 (2004), pp. 424-431
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, et al.
enalidomide in the myelodysplastic síndrome with chromosome 5 q deletion.
N Engl J Med, 355 (2006), pp. 1456-1465
FDA approval for lenalidomide [accessed 2/2008]. Available from: http://www.cancer.gov/cancertopics/druginfo/fda_lenalidomide
J.A. Katzel, P. Hari, D.H. Vesole.
Multiple myeloma: charging toward a bright future.
CA Cancer J Clin, 57 (2007), pp. 301-318
G.J Morgan, S.A. Schey, P. Wu, M. Srikanth, K.J. Phekoo, M. Jenner, et al.
Lenalidomide in combination with cyclophosphamide and dexamethasone, is an effective and tolerated regimenfor myeloma patients.
Br J Haematol, 137 (2007), pp. 268-269
Copyright © 2010. Sociedad Española de Farmacia Hospitalaria
Article options